Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma accompanied by symptoms of acute illness and abnormal chest findings.
It is a lower respiratory tract infection acquired in the community within 24 hours to <2 weeks or occurring ≤48 hours of hospital admission in patients who do not meet the criteria for healthcare-associated pneumonia.
It occurs at the highest rates in the very young and the very old.
Potentially life-threatening especially in older adults and those with comorbid disease.
Assoc Prof Philip Eng, senior consultant respiratory physician at Mt Elizabeth Hospital in Singapore, shares his insights with Pearl Toh on diagnosing and managing pneumonia in the primary care setting.
The novel pleuromutilin antibiotic lefamulin - now in an oral therapy form - has demonstrated a favourable safety and tolerability profile for community-acquired bacterial pneumonia (CABP) in the LEAP* 2 study, the same result seen for intravenous (IV) lefemulin in the original LEAP 1 study.
The tetracycline omadacycline is not inferior to moxifloxacin when used as empirical monotherapy for hospitalized adults with community-acquired bacterial pneumonia, according to the results of a phase III study.
Individuals hospitalized with pneumonia have an elevated risk of developing major adverse cardiovascular events (MACE), with a greater risk among those with bacterial compared with viral pneumonia, according to a recent study presented at AHA 2018.
The pneumonia-causing bacteria, Streptococcus pneumoniae (pneumococcus), can be spread through nose picking and rubbing after exposure of the hands to the bacteria — in addition to the conventionally known route of inhalation of airborne droplets, a study reveals.
New drug applications approved by US FDA as of 1 - 15 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 01 - 15 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Long-term proton-pump inhibitor (PPI) therapy was associated with an increased pneumonia risk among older adults, putting to rest the controversies about the validity of previously reported short-term harms of PPIs, according to a large, longitudinal analysis of electronic medical records.
Individuals using opioid analgesics may be at an elevated risk of invasive pneumococcal disease, particularly those using long-acting, high-potency, immunosuppressive, or high-dose opioids, results of a nested case-control study show.
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from a large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.